Zenas Biopharma (NASDAQ:ZBIO – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.92) per share for the quarter.
Zenas Biopharma Price Performance
Zenas Biopharma stock opened at $8.33 on Friday. The stock has a market cap of $348.19 million and a P/E ratio of -2.35. Zenas Biopharma has a 52 week low of $5.83 and a 52 week high of $26.25.
Wall Street Analyst Weigh In
Several brokerages have recently commented on ZBIO. Guggenheim reiterated a “buy” rating and set a $45.00 target price on shares of Zenas Biopharma in a research note on Wednesday, March 12th. Wedbush initiated coverage on shares of Zenas Biopharma in a report on Thursday. They issued an “outperform” rating and a $35.00 price objective on the stock.
Zenas Biopharma Company Profile
Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
See Also
- Five stocks we like better than Zenas Biopharma
- Canadian Penny Stocks: Can They Make You Rich?
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- What Investors Need to Know to Beat the Market
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- Want to Profit on the Downtrend? Downtrends, Explained.
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Zenas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
